Potent and selective cyclooxygenase-2 inhibitors

Author:  

Publisher: Informa Healthcare

ISSN: 1354-3776

Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.1, 1997-01, pp. : 79-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

These patents disclose a series of diphenylpyridines and diphenylisoxazoles which are reported to be potent and selective cyclooxygenase-2 (COX-2) inhibitors. Among the best derivatives claimed, only compounds in the diphenylisoxazole series exhibit an in vivo biological profile comparable to indomethacin in an inflammatory and analgesia model. Consequently, these inhibitors are of great interest in terms of their in vivo pharmacology, either for use as anti-inflammatory agents or for the treatment of pain with reduced ulcerogenic side-effects.